Health and Healthcare
Stem Cell Stocks Rise, Led By Athersys Inc. (ATHX, NBS, STEM)
Published:
Last Updated:
Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that the company has entered into a deal with Pfizer (NYSE: PFE) to develop Athersys’s MultiStem, an experimental treatment for inflammatory bowel disease. Athersys recieved an intial payment of $6 million in addition to funding for research. Should the program be successful Athersys will recieved as much as $105 million as well as royalties from sales of the drug should it come to mark.
Other stem cell stocks received a big boost from the news. Neostem Inc. (AMEX: NBS), which operates a operates a center for the collection and storage of stem cell, rose as high as 7.6%. StemCells Inc. (NASDAQ: STEM), which attempts to treat organ disorders with stem cells, climbed as high as 7.2%
Garrett W. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
